Careful Selection of Ovarian Cancer Patients for Chemo Before Surgery May Improve Survival Rates

Careful Selection of Ovarian Cancer Patients for Chemo Before Surgery May Improve Survival Rates
The use of neoadjuvant chemotherapy (NACT), or chemo administered before surgery, in patients with ovarian cancer has increased as an alternative to primary cytoreductive surgery (PCS), performed when a woman is diagnosed. But in women with stage 3C disease, NACT correlates with shorter overall survival compared to surgery, according to a recent study published in the Journal

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *